Table 2.
Studies demonstrating the beneficial effects of melatonin preconditioning in MSC‐based therapy for kidney disease
| Condition | References | Year | Animal | Model | Stem cells source | Renal outcomes | MSCs outcomes |
|---|---|---|---|---|---|---|---|
| AKI | Chen83 | 2014 | Rats | Sepsis‐AKI | A‐AMSCs | ↓Inflammatory; ↑Antioxidants; ↓ROS; ↓Apoptosis; ↓Fibrosis; ↓Kidney injury score; ↑Renal function | Not mentioned |
| Zhao84 | 2015 | HK‐2 cells | Cisplatin‐AKI | AMSCs | ↑Proliferation; ↑Migration; ↑Prosurvival and anti‐apoptotic ability | ↑Proliferation; ↑Prosurvival, anti‐apoptotic and antioxidative ability; | |
| Mias53 | 2008 | Rats | I/R‐AKI | BMMSCs | ↑Angiogenesis; ↑Proliferation; ↓Apoptosis; ↑Renal function | ↓Apoptosis; ↑Survival rate; ↑Paracrine ability (b‐FGF, HGF); | |
| CKD | Saberi71 | 2019 | Rats | UUO | BMMSCs | ↓TGF‐β and TNF‐α; ↓α‐SMA; ↑E‐cadherin; ↓Fibrotic areas | ↑Survival rate; ↑Migratory activity |
| Rashed87 | 2018 | Rats | DN | MSCs | ↓TGF‐β; ↑SOD‐1; ↑Beclin‐1; ↑Renal function | ↑Proliferation |
Abbreviations: A‐AMSCs, apoptotic adipose‐derived MSCs; AKI, acute kidney injury; AMSCs, adipose‐derived MSCs; b‐FGF, basic fibroblast growth factor; BMMSCs, bone marrow‐derived mesenchymal stem cells; Cisplatin‐AKI, cisplatin‐induced AKI; CKD, chronic kidney disease; DN, diabetic nephropathy; HGF, hepatocyte growth factor; I/R, ischemia/reperfusion; I/R‐AKI, I/R induced AKI; MSCs, mesenchymal stem cells; ROS, reactive oxygen species; Sepsis‐AKI, sepsis induced AKI; SOD‐1, superoxide dismutase‐1; TGF‐β, tumour growth factor β; TNF‐α, tumour necrosis factor‐ α; UUO, unilateral ureteral obstruction; α‐SMA, α‐smooth muscle actin.